



Agenda Item #8  
Programmatic Tools

Gil Sambrano  
Vice President, Portfolio Development and Review  
California Institute for Regenerative Medicine

**TRANSFORMING**

*medicine*  
*lives*  
*futures*

June 28, 2018




# Presentation Outline

- Overview of Review Process
  - Gil Sambrano
- Discussion of Programmatic Review
  - Jeff Sheehy
- Possible Tools to Support Review
  - Gil Sambrano

# Phases of the Review Process

# Application Review Process



Merit Review:  
GWG

# Is the project scientifically meritorious?

- ✓ Does the project hold the necessary significance and potential for impact?  
*Includes value proposition, unmet medical need*
- ✓ Is the rationale sound?  
*Scientific/clinical basis, supportive data*
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?  
*Adequate resources, quality team, achievable timeline*

# Scoring for DISC and TRAN Applications

- **Score of “85-100”**

*Recommended for funding, if funds are available*

- **Score of “1-84”**

*Not recommended for funding*

Applications are scored by all scientific members of the GWG with no conflict.

The **median** of all individual GWG scores determines final score.

# Scoring for Clinical Applications

- **Score of “1”**

*Exceptional merit and warrants funding.*

- **Score of “2”**

*Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.*

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months**.*

Applications are scored by all scientific members of the GWG with no conflict.

Funding Decision:  
ICOC

# Application Review Subcommittee

## What is programmatic review?

- Subcommittee considers GWG and CIRM recommendations
- Subcommittee may consider additional factors:
  - CIRM mission
  - Portfolio make-up
  - RFA objectives
  - Unmet medical need
  - Budget

What other factors could or should be considered?

# Possible Tools to Support ICOC Subcommittee Review

# Potential Discussion Points

- **Annual Program Budget and Goals**
- **Value Proposition of Proposed Project**
  - *Patient population, competitive landscape*
- **Relevance of Project to Stem Cells**
- **Contribution to CIRM Portfolio**
  - *Disease area, current award overlap*
- **Previous CIRM Support of Project**


# 2018 Clinical Budget Status

## End of June

**Annual Allocation: \$130 million**  
(Additional \$130 planned for 2019)


- Amount Requested Today
- Approved Awards
- Unused Balance

Amounts are shown in millions



# 2018 Clinical Award Targets

## CLIN2 Clinical Trials



## CLIN1 Late Stage Preclinical



 Approved Award       Awaiting Today's Approval

# CLIN2-Example: Phase 1 Clinical Trial of Therapy for (X) Cancer

## Project Summary

<b>Therapy</b>	Gene-modified dendritic cells
<b>Indication</b>	Adult patients with advanced (x) cancer
<b>Goal</b>	Complete a phase 1 clinical trial to assess safety, maximum tolerated dose, and response rate of therapy
<b>Funds Requested</b>	\$10,000,000 (\$400,000 Co-funding)

Maximum funds allowable for this category: \$12,000,000

# CLIN2-Example: Phase 1 Clinical Trial of Therapy for (X) Cancer


**Potential impact:** As stated by the applicant, about 350,000 people in the US are diagnosed with (x) cancer each year. About 75% of patients with (x) cancer will die of the disease within 5 years of diagnosis. If successful, the proposed therapy could impact a majority of (x) cancer patients.

**Value Proposition:** Statement that addresses competitive advantage, advancement over current standard of care, and overall value of proposed therapy .

**Why a stem cell project:** This is a cell therapy where monocytes are used to manufacture the dendritic cell product. Monocytes are capable of differentiation and retain an ability to divide.

# Where does this project (CLIN2-XXXXX) fit into our clinical portfolio?

Adds a clinical trial to “Solid Cancers” category



# Related CIRM Portfolio Projects

Application /Award	Project Stage	Project End Date	Indication	Candidate	Mechanism of Action
Current Application	Phase 1	N/A	Advanced (X) Cancer	Gene modified dendritic cells	Enhanced T cell activation
CLIN2-09577	Phase 1b/2	12/31/21	Advanced Solid Tumors	Anti Cd-47 and cetuximab antibodies	Phagocytosis of cancer stem cells
CLIN1-10893	IND	06/30/19	Solid Tumors	iPSC derived Natural Killer Cells	NK cell mediated elimination of cancer cells

# Previous CIRM Funding for Project

Project Stage	Project Outcome	Project End Date
Translational	Conducted Pre-IND Meeting	01/01/2016
IND-Enabling	IND Filed	01/01/2018

{CIRM funds have not been previously awarded to this team or to earlier stages of this project.}

# CLIN2-Example: Phase 1 Clinical Trial of Therapy for (X) Cancer

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	15
2	0
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$10,000,000\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.

# CLIN2-Example: Phase 1 Clinical Trial of Therapy for (X) Cancer

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	8
2	6
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$10,000,000\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.

## CLINICAL TRIAL APPLICATIONS

App#	Indication	Therapy	Project Stage	GWG Score [Votes]	Amount Requested
CLIN2-example	Sickle cell disease	Cell therapy (HSC)	Ph 1	1 [7-5-0]	\$5,000,000
CLIN2-example1	(X) cancer	Cell therapy	Ph 1	1 [15-0-0]	\$10,000,000
CLIN2-example2	Osteoarthritis	Small molecule drug	Ph 1	1 [8-6-0]	\$8,000,000

## LATE STAGE PRECLINICAL APPLICATIONS

App#	Indication	Therapy	Project Stage	GWG Score [Votes]	Amount Requested
CLIN1-xxxyyy	Colon cancer	Cell therapy (MSC)	IND	1 [12-2-1]	\$4,000,000
CLIN1-aaabbc		Cell therapy (T cells)	IND	1 [8-5-2]	\$3,500,000